Chemomab Therapeutics Files Q2 2026 Results and Updates SEC Registrations
I'm LongbridgeAI, I can summarize articles.Chemomab Therapeutics filed Form 6-K with the SEC on August 19, 2026, reporting unaudited Q2 2026 financial results. The company reported total assets of $10.2 million and a net loss of $3.9 million for the first half of 2026, reflecting continued operating losses and cash burn. These disclosures were incorporated into existing shelf registration statements to maintain financing flexibility. Analysts rate the stock as a Buy with a $5.00 target, while TipRanks' AI suggests a Neutral stance due to weak financial performance offset by low debt.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Chemomab Therapeutics ( (CMMB) ) has issued an update.
On August 19, 2026, Chemomab Therapeutics filed a Form 6‑K with the U.S. Securities and Exchange Commission, reporting unaudited condensed consolidated financial results for the three‑ and six‑month periods ended June 30, 2026. The filing also included management’s discussion and analysis of its operating performance and a corporate update press release, and incorporated these disclosures into several existing shelf registration statements, underscoring the company’s ongoing financing flexibility and transparency for investors.
The interim statements showed total assets of $10.2 million and shareholders’ equity of $8.7 million as of June 30, 2026, down from $13.8 million and $12.3 million at year‑end 2025, reflecting continued operating losses. For the first half of 2026, Chemomab recorded a net loss of $3.9 million on operating expenses of $4.1 million, highlighting the cash‑consuming nature of its R&D‑driven business model and the importance of its SEC registrations for potential future capital raises as it advances its clinical programs.
The most recent analyst rating on (CMMB) stock is a Buy
with a $5.00 price target.
To see the full list of analyst forecasts on Chemomab Therapeutics stock,
see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses, and sustained cash burn implying financing dependence), partially offset by a low-debt balance sheet and improving loss/burn trends. Technicals are supportive due to strong price momentum above key moving averages, but overbought signals (high RSI/Stoch) temper the technical contribution. Valuation is constrained by negative earnings (negative P/E) and no indicated dividend yield.
To see Spark’s full report on CMMB stock,
click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is a clinical‑stage biotechnology company headquartered in Tel Aviv, Israel, that focuses on developing therapies for fibrotic and inflammatory diseases. Its shares trade in the U.S. via American Depositary Shares, each representing 80 ordinary shares, giving the company access to international capital markets.
Average Trading Volume: 131,693
Technical Sentiment Signal: Hold
Current Market Cap: $13.82M
Learn more about CMMB stock on TipRanks’ Stock Analysis page.